© 1996 British Society for Rheumatology
research-article |
CYCLOSPORIN A IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF AN OPEN CLINICAL STUDY
Department of Internal Medicine III and Institute for Clinical Immunology and Rheumatology, University Erlangen-Nuremberg Erlangen, Germany
Correspondence to:
Correspondence to: Karin Manger, Medizinische Klinik III, Krankenhausstraße 12, D-91054 Erlangen, Germany.
In order to define the effects and safety of cyclosporin A (CsA) in systemic lupus erythematosus (SLE), we conducted an open clinical trial with 16 SLE patients. During an observation period of up to 64 months and an average treatment period of 30.3 months, 16 SLE patients, who did not have adequate disease control or experienced side-effects with their previous immunosuppressive therapy, were treated with CsA (3–5 mg/kg). In 3/16 patients, CsA treatment was discontinued because of side-effects, in two because of inefficacy and in 2/16 because of a pregnancy. Four out of 16 patients had a flare of disease during CsA therapy 7, 24, 36 and 40 months after initial response to therapy; one patient stopped CsA treatment after 54 months of successful disease control. Four out of 16 patients are still on CsA. The best beneficial effect was observed in 10 patients with proteinuria, which decreased from 4.7 ± 2.6 to 1.5 ± 1.1 g/24h. In 3/3 patients with thrombocytopenia and 3/3 patients with leucocytopenia, platelets and leucocytes returned to normal values. The most frequent side-effects were hypertension and deterioration of renal function (3/16) and hypertrichosis (5/16). According to the preliminary results of this study, CsA was well tolerated and able to control disease activity over an extended time period. These data should encourage investigators to perform a multicentre controlled trial on CsA therapy in SLE.
KEY WORDS: Systemic lupus erythematosus, Therapy, Cyclosporin A, Proteinuria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Moroni, A. Doria, and C. Ponticelli Cyclosporine (CsA) in lupus nephritis: assessing the evidence Nephrol. Dial. Transplant., January 1, 2009; 24(1): 15 - 20. [Full Text] [PDF]
|
|
|
|
 |
|
 V Baca, T Catalan, M Villasis-Keever, G Ramon, A. Morales, and F Rodriguez-Leyva Effect of Low-Dose Cyclosporine A in the Treatment of Refractory Proteinuria in Childhood-Onset Lupus Nephritis Lupus, August 1, 2006; 15(8): 490 - 495. [Abstract] [PDF]
|
|
|
|
|
|
L Quartuccio, S Sacco, N Franzolini, A Perin, G Ferraccioli, and S De Vita Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus Lupus, February 1, 2006; 15(2): 76 - 79. [Abstract] [PDF]
|
|
|
|
|
|
B Griffiths and P Emery The treatment of lupus with cyclosporin A Lupus, March 1, 2001; 10(3): 165 - 170. [Abstract] [PDF]
|
|
|
|
|
|
F Conti, R Priori, C Alessandri, F R Spinelli, E Medda, and G Valesini Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A Lupus, November 1, 2000; 9(9): 676 - 680. [Abstract] [PDF]
|
|
|
|
 |
|
 S J Morton and R J Powell An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use Ann Rheum Dis, June 1, 2000; 59(6): 487 - 489. [Abstract] [Full Text]
|
|
|
|
|
|
D Hallegua, D J Wallace, A L Metzger, R Z Rinaldi, and J R Klinenberg Cyclosporine for lupus membranous nephritis:experience with ten patients and review of the literature Lupus, May 1, 2000; 9(4): 241 - 251. [Abstract] [PDF]
|
|
|
|
|
|
Y Sherer, P Langevitz, Y Levy, F Fabrizzi, and Y Shoenfeld Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin Lupus, May 1, 1999; 8(4): 324 - 327. [Abstract] [PDF]
|
|
|
|
|
|
M Duddridge and R J Powell Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases Ann Rheum Dis, November 1, 1997; 56(11): 690 - 692. [Abstract] [Full Text]
|
|